Proline

Future Focused: Revolutionary New Fitness Line, Awards & Memorable Moments at Le-Vel's Annual Convention

Retrieved on: 
Monday, April 29, 2024
Advocate, Proline, Senior, Ultimate, Health, Heart, Dream, United States Army, Motivational speaker, Dance, Speech, Amputation, Social media, Strategy, Ship, Nightclub

FRISCO, Texas, April 29, 2024 /PRNewswire/ -- Le-Vel's highly anticipated annual event, THRIVEpalooza, returned to New Orleans for another unforgettable experience from April 18-20, 2024 at the Hilton Riverside. With a full schedule of incredible parties and monumental announcements, this year's THRIVEpalooza exceeded all expectations and left attendees inspired, motivated, and ready to conquer their goals.

Key Points: 
  • This exclusive dinner honored the dedication and hard work of these top Brand Promoters, highlighting their incredible success stories and contributions to the community.
  • Followed by the Mardi Gras Masquerade Welcome Party Friday evening, featuring a live concert by the Party Crashers.
  • Saturday's main stage presentation was a highlight of the event, with discussions surrounding the future and going forward.
  • As we stand on the threshold of the future, I am energized by the boundless possibilities that lie ahead.

Festo's smart proximity switch commissions itself, for time savings that add up

Retrieved on: 
Thursday, April 11, 2024
Proline, CNC, Normality (behavior), PNP, Festo, Polymer, NPN, Logic, Multimedia, PLC, Perspiration, Material

MISSISSAUGA, ON, April 11, 2024 /PRNewswire-PRWeb/ -- There are indeed rewards for machine builders who sweat the small stuff. The latest iterations of many tiny but essential components like sensors, cameras and switches can pack a great deal of innovation for their diminutive size.

Key Points: 
  • With many proximity switches on each Pro-Line machine, the time savings from no longer having to make this follow-up adjustment really add up.
  • This feature-rich proximity switch is one example of the advances Festo is making in designing next-generation components, large or small.
  • Proximity switches are affixed to pneumatic actuators to signal the PLC or controller that the full extension of the piston has been reached.
  • However, with vinyl or polymers that have some give, a soft stop can be a challenge for a legacy switch.

Alienware Redesigns m16 R2 with Stealth Mode - Supercharges x16 R2, m18 R2

Retrieved on: 
Monday, January 8, 2024
Atmos, Cloud, R2, RGB, AWCC, Software, Student, IEEE 802.11be, QHD, Xbox, Catalog, DNA, Ultra, CPU, GeForce, FHD, Discord, Atmosphere, Dolby Vision, Deep learning super sampling, Cryo, Multimedia, DLC, F2, Human, Love, Xbox Game Pass, MUX, Dolby Atmos, Heat, CES, Dell, Windows 11, Digital, Travel, EA Play, Athlete, Friends, R16, Language, Perspiration, Alienware, FAQ, GPU, Windows 10, Immersion, NVIDIA, TB, DLSS, Credit, Wind, HDR, Proline, Express, Element, Gallium, Lighting, Stealth mode, Video game

Meet Alienware's latest product portfolio:

Key Points: 
  • Meet Alienware's latest product portfolio:
    Three new gaming notebooks debut — the redesigned Alienware m16 R2, the ultra-premium x16 R2, and our performance juggernaut, the m18 R2.
  • Meet the m16 R2, a redesigned gaming laptop that prioritizes performance, flexibility and portability, while preserving the Alienware advantages our customers have come to love.
  • The refined Alienware x16 R2 fortifies this status with faster performance, improved cooling and greater future readiness.
  • x Latest generation systems include: m16 R2, m18 R2, x16 R2 and R16, as well as the generation prior: x14 R2, x16, & m18
    View original content to download multimedia: https://www.prnewswire.com/news-releases/alienware-redesigns-m16-r2-with...

EQS-News: Schletter International B.V.: SCHLETTER PRESENTS AGRI-PV, SOLAR CARPORTS AND 3D-METAVERSE AT INTERSOLAR EUROPE

Retrieved on: 
Monday, June 12, 2023
Intersolar, Sunrider, Exhibition, Electricity, PV, Proline, A6, Vehicle registration plates of Nepal, Hans Michael Schletterer, House, Renewable energy

The Schletter Group is launching two major products at this year’s Intersolar Europe: one is a newly developed Agri-PV system and the other is a solar carport.

Key Points: 
  • The Schletter Group is launching two major products at this year’s Intersolar Europe: one is a newly developed Agri-PV system and the other is a solar carport.
  • "A key challenge in the development of PV energy is generating as much solar power as possible while utilizing as little space as possible", says Schletter CEO Florian Roos.
  • “Solar carports not only generate renewable energy on land already developed but are a crucial building block to the expansion of e-mobility.
  • The Schletter Group is exhibiting from June 14th to 16th at Intersolar Europe in Munich in hall A6, stand 180.

Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, PTSD, Clinical research associate, MDD, Risk, Food, Proline, Major depressive disorder, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Post-traumatic stress disorder, University, Bipolar disorder, Lithium, Pharmaceutical industry

Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.

Key Points: 
  • Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.
  • Mr. Jackman will appear on the Making Money with Charles Payne show that airs between 2 p.m. and 3 p.m.
  • 2023 is shaping up to be an exciting year as we move forward with both clinical programs.
  • Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers, bipolar disorder, MDD and PTSD.

World Amino Acids Markets, 2019, 2022 and 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Vitamins, Supplements, Health, Phenylalanine, Glutamine, Tyrosine, Serine, Alanine, Proline, Lysine, Isoleucine, Valine, Aladdin (food & beverage containers), Arginine, Cysteine, Histidine, Protein, Leucine, Aspartic acid, Organic acid, Glutamic acid, Amino acid, Threonine, Glycine, Tryptophan, Asparagine, Methionine, Cosmetics, Dietary supplement

The "Amino Acids World Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Amino Acids World Market" report has been added to ResearchAndMarkets.com's offering.
  • The report analyzes the market for Amino Acids at high level by product type/sub-type, end-use application and geographic region.
  • The market is studied for historical/current trends and future forecast in terms of and value in US$ for 2019, 2022 and 2026.
  • The 20 core amino acids that are found within proteins include essential amino acids (arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) and non-essential amino acids (alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine and tyrosine).

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Monday, October 31, 2022
Mental Health, FDA, Health, Clinical Trials, General Health, Pharmaceutical, Safety, Immunization, Injection, Proline, Amyloid, Drug Quality and Security Act, Food, Inflammation, Brain, Securities Act of 1933, Investigational New Drug, Nature, Charles River Laboratories, U.S. Securities and Exchange Commission, Leukapheresis, Patient, Forward-looking statement, DC, Dementia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, IIA, Membrane, Immunotherapy, Securities Exchange Act of 1934, University, FDA, Bipolar disorder, IND, Post-traumatic stress disorder, Major depressive disorder, Risk, MDD, PTSD, Meningoencephalitis, Monocyte, Nasdaq, Lithium, Pharmaceutical industry, Vaccine

We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.

Key Points: 
  • We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.
  • We are advancing the process and expect that the first patient will be dosed in the first quarter of 2023.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The IND supports initial deployment of a Phase I/IIA clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group study.

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Thursday, September 29, 2022
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, Safety, Bipolar disorder, Injection, Meningoencephalitis, Brain, FDA, Food, Drug Quality and Security Act, MDD, U.S. Securities and Exchange Commission, IND, Antibody, Nature, Proline, Securities Act of 1933, DC, Immunization, Immunotherapy, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Patient, Risk, Major depressive disorder, Nasdaq, Dementia, Post-traumatic stress disorder, Amyloid, Monocyte, University, Immune system, Leukapheresis, PTSD, Lithium, Human, Charles River Laboratories, Vaccine, Pharmaceutical industry

The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.

Key Points: 
  • The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The submitted IND supports initial deployment of a clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, Phase I/IIA clinical trial.
  • ALZN002 immunotherapy is intended to treat patients diagnosed with Alzheimers by inducing the patients own antibodies.

Fragment-Based Drug Discovery -- Hitting Targets Using the Right Chemistry and Expertise Alliances, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, September 26, 2022
Therapy, Weizmann Institute of Science, Founder CEO, Proline, Industry, Biophysics, Drug discovery, CEO, Protein, Cysteine, Food, MED, Crystallography, Dietary supplement, Fine chemical

TORONTO, Sept. 26, 2022 /PRNewswire-PRWeb/ -- Fragment Based Drug Discovery (FBDD) has become of increasing importance and interest in the past decade for hit finding and optimization. FBDD led to approved therapeutics and numerous drug candidates. It has empowered the industry to address targets that had previously been deemed "undruggable".

Key Points: 
  • The featured speakers will discuss innovations from fragment identification to lead optimization stage to identify preclinical drug candidates.
  • TORONTO, Sept.26, 2022 /PRNewswire-PRWeb/ -- Fragment Based Drug Discovery (FBDD) has become of increasing importance and interest in the past decade for hit finding and optimization.
  • Join this webinar to learn how fragment-based drug discovery solutions such as DRIVE-SM enable the identification, characterization, design and optimization of fragments into a preclinical drug candidate.
  • For more information, or to register for this event, visit Fragment-Based Drug Discovery Hitting Targets Using the Right Chemistry and Expertise Alliances.

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Pharmaceutical, Health, Mental Health, Securities Exchange Act of 1934, Bipolar disorder, LLC, Securities Act of 1933, MDD, U.S. Securities and Exchange Commission, Nature, Company, Compliance, Proline, Forward-looking statement, Letter, Risk, Major depressive disorder, Post-traumatic stress disorder, University, Lithium, PTSD, Pharmaceutical industry, Nasdaq

As previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Requirement because the bid price for the Companys common stock had closed below $1.00 per share for the previous 30 consecutive business days.

Key Points: 
  • As previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Requirement because the bid price for the Companys common stock had closed below $1.00 per share for the previous 30 consecutive business days.
  • To regain compliance with the Minimum Bid Price Requirement, the Company was required to maintain a minimum closing bid price of the Company's common stock of at least $1.00 for a minimum of ten consecutive business days.
  • The Compliance Notice confirmed that the closing bid price of the Company's common stock has been at $1.00 per share or greater for 10 consecutive business days from September 7 through September 20, 2022, the Company has regained compliance with the Minimum Bid Price Requirement.
  • Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers, bipolar disorder, MDD and PTSD.